The FDA has asked for more information
from Regeneron (REGN
) about the use of its autoinflammatory drug Arcalyst to treat joint pain caused by gout medicines. The FDA has concerns about Arcalyst's links to cancer. The drug is already approved to treat a rare genetic autoinflammatory disease; extending its use for gout could have added up to $200M a year in sales.